Alnylam Pharmaceuticals Aktie
| 293,20USD | -0,60USD | -0,20% |
WKN: A0CBCK / ISIN: US02043Q1076
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 665 | 2 002 | 2 100 | 2 230 | 2 500 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,51 | 0,52 | 0,87 | 1,01 | 1,49 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 809 | 2 692 | 2 983 | 3 295 | 4 051 |
| Summe Anlagevermögen | 835 | 854 | 847 | 1 007 | 975 |
| Summe Aktiva | 3 643 | 3 546 | 3 830 | 4 302 | 5 026 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 3 055 | 3 705 | 4 051 | 4 235 | 4 236 |
| Summe Eigenkapital | 588 | -158 | -221 | 67 | 789 |
| Summe Passiva | 3 643 | 3 546 | 3 830 | 4 302 | 5 026 |
Adresse
| 675 West Kendall Street, 02142 Cambridge | |
| Telefon | +1 (617) 551-8200 |
| Internet | http://www.alnylam.com |
Management
|
Amy L. Schulman
Chairman |
|
Benjamin F. Cravatt
Director |
|
Bryan A. Supran
Secretary, Chief Legal Officer & Executive VP |
|
Charles Elliott Sigal
Independent Director |
|
Christine Regan Lindenboom
Chief Corporate Communications Officer |
|
Colleen Coxson
Country Manager |
|
Colleen F. Reitan
Independent Director |
|
David E. I. Pyott
Independent Director |
|
Dennis Arthur Ausiello
Independent Director |
|
Jeffrey V. Poulton
Executive VP, Chief Financial & Accounting Officer |
|
Joshua Brodsky
VP-Investor Relations & Corporate Communications |
|
Kevin Fitzgerald
Chief Scientific Officer & Executive VP |
|
Margaret A. Hamburg
Independent Director |
|
Martin Maier
Senior Vice President-Oncology |
|
Melissa McLaughlin
Chief Human Resources Officer |
|
Muthiah Manoharan
Senior Vice President-Drug Discovery |
|
Olivier Brandicourt
Independent Director |
|
Peter N. Kellogg
Independent Director |
|
Piyush Sharma
Chief Ethics & Compliance Officer |
|
Pushkal P. Garg
EVP, Chief Research & Development Officer |
|
Stuart A. Arbuckle
Independent Director |
|
Timothy J. Maines
Chief Technical Operations & Quality Officer |
|
Tolga Tanguler
Chief Commercial Officer & Executive VP |
|
Vasant Jadhav
Senior Director-Research |
|
Yvonne L. Greenstreet
Chief Executive Officer & Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.